VEGFA and age-related macular degeneration: Although clinical examination of AMD have indicated that the fovea tend to remain uninvolved by the RPE atrophic process until late in the disease course and follow-up period of anti-VEGF therapy [13, 14, 19], because RPE atrophy seems to progress over time [12], the long-term effect of these treatments on the central VA needs to be ascertained for the long term.